Literature DB >> 10524695

Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

P Cacoub1, T Poynard, P Ghillani, F Charlotte, M Olivi, J C Piette, P Opolon.   

Abstract

OBJECTIVE: To assess the prevalence of clinical and biologic extrahepatic manifestations of hepatitis C virus (HCV) infection and to identify associations between clinical and biologic manifestations.
METHODS: To analyze the natural history of extrahepatic manifestations of HCV infection, we reviewed only the data recorded prospectively during the first visit of 1,614 patients with chronic HCV infection, coming from a single monocenter cohort. Exclusion criteria were positivity for hepatitis B surface antigen or human immunodeficiency virus. The prevalence of dermatologic, rheumatologic, neurologic, and nephrologic manifestations; diabetes; arterial hypertension; autoantibodies; and cryoglobulins were assessed. Then, using multivariate analysis, we identified demographic, biochemical, immunologic, virologic, and liver histologic factors associated with the presence of extrahepatic manifestations.
RESULTS: At least 1 clinical extrahepatic manifestation was observed in each of 1,202 patients (74%). Five manifestations had a prevalence >10%: arthralgia (23%), paresthesia (17%), myalgia (15%), pruritus (15%), and sicca syndrome (11%). Four biologic abnormalities had a prevalence >5%: cryoglobulins (40%), antinuclear antibodies (10%), low thyroxine level (10%), and anti-smooth muscle antibodies (7%). Only vasculitis, arterial hypertension, purpura, lichen planus, arthralgia, and low thyroxine level were associated with cryoglobulin positivity. By univariate and multivariate analyses, the most frequent risk factors for the presence of clinical and biologic extrahepatic manifestations were age, female sex, and extensive liver fibrosis.
CONCLUSION: Extrahepatic clinical manifestations are frequently observed in HCV patients and involve primarily the joints, muscles, and skin. The most frequent immunologic abnormalities include mixed cryoglobulins, antinuclear antibodies, and anti-smooth muscle antibodies. The most frequent risk factors for the presence of clinical and biologic extrahepatic manifestations are advanced age, female sex, and extensive liver fibrosis.

Entities:  

Mesh:

Year:  1999        PMID: 10524695     DOI: 10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  127 in total

1.  Hepatitis C virus treatment complicated by rheumatoid arthritis.

Authors:  Meredith Borman; Mark G Swain
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

2.  Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN.

Authors:  Mohamad Zaidan; Benjamin Terrier; Agnieszka Pozdzik; Thierry Frouget; Nathalie Rioux-Leclercq; Christian Combe; Sébastien Lepreux; Aurélie Hummel; Laure-Hélène Noël; Isabelle Marie; Bruno Legallicier; Arnaud François; Antoine Huart; David Launay; Gilles Kaplanski; Frank Bridoux; Philippe Vanhille; Raifah Makdassi; Jean-François Augusto; Philippe Rouvier; Alexandre Karras; Chantal Jouanneau; Marie-Christine Verpont; Patrice Callard; Fabrice Carrat; Olivier Hermine; Jean-Marc Léger; Xavier Mariette; Patricia Senet; David Saadoun; Pierre Ronco; Isabelle Brochériou; Patrice Cacoub; Emmanuelle Plaisier
Journal:  J Am Soc Nephrol       Date:  2015-08-10       Impact factor: 10.121

3.  Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.

Authors:  M Zehairy; E Soliman; A Daghaidy
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

Review 4.  Infection-related vasculitis.

Authors:  Omondi Oyoo; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

5.  The diversity of autoantibodies to P-ribosomal: the infectious-autoimmunity plot.

Authors:  Yehuda Shoenfeld
Journal:  J Mol Med (Berl)       Date:  2007-09       Impact factor: 4.599

6.  Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.

Authors:  Youssef K Ahmad; Salwa Tawfeek; Mohamed Sharaf-Eldin; Hassan E Elbatea; Abdelrahman Kobtan; Ferial El-Kalla; Rehab Badawi; Sherief Abd-Elsalam
Journal:  Hosp Pharm       Date:  2017-04

Review 7.  [Pruritus with systemic diseases].

Authors:  T Mettang; M Streit; E Weisshaar
Journal:  Hautarzt       Date:  2006-05       Impact factor: 0.751

8.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

9.  B cell non-Hodgkin's lymphoma in chronic hepatitis C virus patients: An interesting relationship.

Authors:  Hassan S Hamdy; Nadia A Abdelkader; Amal Mansour; Enas H Allam; Hisham M El-Wakiel; Dina Elshenawy
Journal:  Indian J Gastroenterol       Date:  2015-04-29

Review 10.  Hepatitis C virus-induced cryoglobulinemia.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  Kidney Int       Date:  2009-07-15       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.